NewsBite analysis · BioTech, HealthTech · New Product
CNBC
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%
Moderna and Merck have announced promising initial results from their personalized cancer vaccine trial targeting melanoma, which showed an ability to significantly prolong the time patients live without recurrence compared to the standard treatment. This success marks a crucial step toward potential FDA approval, as the companies now plan to present findings at medical meetings. Initial trial data has already had a notable impact on stock prices, reflecting positive sentiment in the market for this innovative treatment approach.
Act nowConfidence: HighShort term horizon
Published 19 Aug 2026, 11:55 UTC3 min read
Visit original article ↗Lead image — CNBC
Summary
TL;DR
- Personalized cancer vaccine met phase three trial goals for melanoma.
- Combination with Merck’s Keytruda showed extended disease-free survival.
- Moderna's stock increased approximately 100% following the announcement.
- Merck shares rose by over 8% in premarket trading.
- The regimen reduces risk of cancer spreading to distant sites.
Interesting facts
- Melanoma accounts for a small percentage of skin cancers but causes the majority of deaths.
- This vaccine targets unique mutations in each patient's tumor for personalized treatment.
- The treatment approach builds on years of research from both companies.